Jazz Pharmaceuticals (JAZZ) Gross Margin (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Gross Margin of 87.45% for Q1 2026, down 89.0% year-over-year from 795.04% in Q1 2025, and little changed quarter-over-quarter from 87.18% in Q4 2025.
Powered by 
Analysis
Jazz Pharmaceuticals (JAZZ) Gross Margin (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Gross Margin history runs 17 years deep, the most recent figure standing at 87.45% for Q1 2026.
- In Q1 2026, Gross Margin fell 89.0% year-over-year to 87.45%; the TTM figure through Mar 2026 stood at 88.0% (down 81.0% YoY), while the FY2025 annual figure was 88.21%, down 84.0% from the prior year.
- Gross Margin for Q1 2026 stood at 87.45%, roughly flat from 87.18% in the prior quarter.
- The five-year high for Gross Margin was 89.81% in Q2 2023, with the low at 82.78% in Q4 2022.
- The 5-year median for Gross Margin is 88.35% (2025), against an average of 87.77%.
- The sharpest annual moves came in 2022 and 2023: Gross Margin sank 755 bps in 2022, then jumped 662 bps in 2023.
- Jazz Pharmaceuticals' Gross Margin stood at 82.78% in 2022, then rose by 8 bps to 89.4% in 2023, then decreased by 1 bps to 88.17% in 2024, then slipped by 1 bps to 87.18% in 2025, then rose by 0 bps to 87.45% in 2026.
- Business Quant data shows JAZZ's Gross Margin at 87.45% in Q1 2026, 87.18% in Q4 2025, and 88.56% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Jazz Pharmaceuticals | 15.60 Bn | 13.98 Bn | 1.09 Bn | 90.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 90.37% |
| Mar 31, 2026 | 87.45% |
| Dec 31, 2025 | 87.18% |
| Sep 30, 2025 | 88.56% |
| Jun 30, 2025 | 88.88% |
| Mar 31, 2025 | 88.35% |
| Dec 31, 2024 | 88.17% |
| Sep 30, 2024 | 89.42% |
| Jun 30, 2024 | 89.27% |
| Mar 31, 2024 | 89.41% |
| Dec 31, 2023 | 89.40% |
| Sep 30, 2023 | 89.49% |
| Jun 30, 2023 | 89.81% |
| Mar 31, 2023 | 85.59% |
| Dec 31, 2022 | 82.78% |
| Sep 30, 2022 | 85.79% |
| Jun 30, 2022 | 86.69% |
| Mar 31, 2022 | 85.83% |
| Dec 31, 2021 | 84.82% |
| Sep 30, 2021 | 82.67% |